COLUMVI

This brand name is authorized in Austria, Canada, Estonia, France, Croatia, Ireland, Israel, Lithuania, Romania, United Kingdom, United States

Active ingredients

The drug COLUMVI contains one active pharmaceutical ingredient (API):

1 Glofitamab UNII 06P3KLK2J8 - GLOFITAMAB

Glofitamab is a bispecific monoclonal antibody that binds bivalently to CD20 expressed on the surface of B cells and monovalently to CD3 in the T-cell receptor complex expressed on the surface of T cells. By simultaneous binding to CD20 on the B cell and CD3 on the T cell, glofitamab mediates the formation of an immunological synapse with subsequent T-cell activation and proliferation, secretion of cytokines and release of cytolytic proteins that results in the lysis of CD20-expressing B cells. Read about Glofitamab

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
COLUMVI Concentrate for solution for infusion	European Medicines Agency (EU)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
L01FX28		L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01F Monoclonal antibodies and antibody drug conjugates → L01FX Other monoclonal antibodies
Discover more medicines within L01FX28

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: CA	Health Products and Food Branch	Identifier(s): 02536552, 02536560
Country: EE	Ravimiamet	Identifier(s): 1898758, 1898769
Country: FR	Base de données publique des médicaments	Identifier(s): 66831305, 68364042
Country: IL	מִשְׂרַד הַבְּרִיאוּת	Identifier(s): 21017, 21018
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1097398, 1097399
Country: RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	Identifier(s): W69689001, W69690001
Country: US	FDA, National Drug Code	Identifier(s): 50242-125, 50242-127